Will A Powerful New Ministry Lead To A Favorable Regulatory Environment In China?
This article was originally published in PharmAsia News
With its organizational structure in place and a roadmap of responsibilities published, China’s now powerful National Health and Family Planning Commission could bring about a new age of regulatory efficiency.
You may also be interested in...
In China, A Province's Drastic Price Cut Model Is Being Modified To Fit A Nationwide System: A Look At The Anhui Model
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.